Specialty code 183500000X · Vacaville, CA
NPI
1902918295
Since 2006
Specialty
Specialty code 183500000X
Code 183500000X
Group practices
0
Medicare group memberships
Hospitals
0
Hospital affiliations
1 Quality Dr
Vacaville, CA, 95688
Phone (707) 624-2013
Medicare paid
-
No Medicare services published
Medicare patients
-
Drug cost, 2024
$424K
2,901 prescriptions
Company payments
-
None reported
Medicare prescription drug claims, 2024
In 2024, the drug Shawn K Kanehira-Mar prescribed most often to Medicare patients was Atorvastatin Calcium, with 383 prescriptions and refills. In total Shawn K Kanehira-Mar wrote 2,901 Medicare prescriptions that cost $424K.
| Drug |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-12-03.
| Claims |
|---|
| 30-day fills |
|---|
| Patients |
|---|
| Cost |
|---|
| Atorvastatin Calcium Generic | 383 | 1,267 | 149 | $4,514 |
| Ozempic Semaglutide | 278 | 291 | 57 | $206K |
| Metformin Hcl Er Metformin Hcl | 266 | 869 | 112 | $2,485 |
| Metformin Hcl Generic | 204 | 653 | 77 | $2,695 |
| Glipizide Generic | 179 | 589 | 77 | $2,198 |
| Jardiance Empagliflozin | 156 | 477 | 56 | $78K |
| Lisinopril Generic | 154 | 502 | 61 | $1,791 |
| Humulin N Insulin Nph Human Isophane | 152 | 458 | 69 | $31K |
| Losartan Potassium Generic | 124 | 392 | 48 | $1,512 |
| Simvastatin Generic | 103 | 342 | 37 | $1,231 |
| Amlodipine Besylate Generic | 102 | 321 | 38 | $1,211 |
| Humulin R Insulin Regular, Human | 84 | 208 | 33 | $13K |
| Glipizide Er Glipizide | 77 | 240 | 34 | $2,045 |
| Veo Insulin Syringe Syringe-Needle,insulin,0.5 Ml | 74 | 212 | 46 | $2,042 |
| Insulin Glargine-Yfgn Generic | 61 | 177 | 43 | $11K |
Brand drugs: 837 claims; generic drugs: 1,882 claims.
Money and other things of value reported by the companies
No payments from drug or medical device companies to Shawn K Kanehira-Mar were reported in the years we have.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.